MET in type 1 papillary renal cell carcinoma (Homo sapiens)

From WikiPathways

Revision as of 22:47, 23 March 2018 by Khanspers (Talk | contribs)
Jump to: navigation, search
1, 3-5, 7...22222Epithelial cell of proximal renal tubuleEndothelial cellNucleusCell junctionCell polarityActin cytoskeletonMotilityInvasionNegative MetregulationGene fusionsSurvivalMigrationVEGFRPLCG1MAPK8PIP3foretinibCBLHGFSTAT3PTPsPIK3CAVEGFPKCMETGAB1PGRB2SOS1SOS2HRASKRASNRASCRKCRKLRAPGEF1PTPN11RAP1ARAP1BARAFRAF1BRAFRAC1CDC42PAK4BUB1B-PAK6PAK1PAK2PAK3PAK6PAK5MAP2K1MAP2K2PPPPMAPK1PPMAPK3PPPIK3CBPIK3CDPIK3R1PIK3R2PIK3R3PIK3R3AKT1AKT2AKT3BADETS1PPJUNPCell cycle progressionProliferationALKSTRNINSL3JAK3TCEB3RPL11C8orf3415tivantinibCRKTransformationPTK2SRCDAGIP3Ca2+MET


Description

MET activation by its ligand HGF induces MET kinase catalytic activity, which triggers transphosphorylation of the tyrosines Tyr 1234 and Tyr 1235. These two tyrosines engage various signal transducers, thus initiating a whole spectrum of biological activities driven by MET, collectively known as the invasive growth program; proliferation and survival (resistance to apoptotic signals), increased cell motility, cell dissociation (scattering), epithelial tubulogenesis, infiltration of tissues, and stimulation of angiogenesis (Appleman et al). The transducers interact with the intracellular multisubstrate docking site of MET either directly, such as GRB2, SHC, SRC, and the p85 regulatory subunit of PI3K, or indirectly through the scaffolding protein GAB1.

Tyr 1349 and Tyr 1356 of the multisubstrate docking site are both involved in the interaction with GAB1, SRC, and SHC, while only Tyr 1356 is involved in the recruitment of GRB2, phospholipase C γ (PLC-γ), p85, and SHP2. GAB1 is a key coordinator of the cellular responses to MET and binds the MET intracellular region with high avidity, but low affinity. Upon interaction with MET, GAB1 becomes phosphorylated on several tyrosine residues which, in turn, recruit a number of signalling effectors, including PI3K, SHP2, and PLC-γ. GAB1 phosphorylation by MET results in a sustained signal that mediates most of the downstream signaling pathways. (Description adapted from Wikipedia MET is a proto-oncogene, meaning that regulated expression of the wild-type allele plays a role in normal physiologic processes, and malignant transformation occurs when MET activity is increased in- appropriately and/or constitutively activated (Appleman et al).

Quality Tags

Ontology Terms

 

Bibliography

View all...
  1. Organ SL, Tsao MS; ''An overview of the c-MET signaling pathway.''; Ther Adv Med Oncol, 2011 PubMed
  2. Linehan WM, Spellman PT, Ricketts CJ, Creighton CJ, Fei SS, Davis C, Wheeler DA, Murray BA, Schmidt L, Vocke CD, Peto M, Al Mamun AA, Shinbrot E, Sethi A, Brooks S, Rathmell WK, Brooks AN, Hoadley KA, Robertson AG, Brooks D, Bowlby R, Sadeghi S, Shen H, Weisenberger DJ, Bootwalla M, Baylin SB, Laird PW, Cherniack AD, Saksena G, Haake S, Li J, Liang H, Lu Y, Mills GB, Akbani R, Leiserson MD, Raphael BJ, Anur P, Bottaro D, Albiges L, Barnabas N, Choueiri TK, Czerniak B, Godwin AK, Hakimi AA, Ho TH, Hsieh J, Ittmann M, Kim WY, Krishnan B, Merino MJ, Mills Shaw KR, Reuter VE, Reznik E, Shelley CS, Shuch B, Signoretti S, Srinivasan R, Tamboli P, Thomas G, Tickoo S, Burnett K, Crain D, Gardner J, Lau K, Mallery D, Morris S, Paulauskis JD, Penny RJ, Shelton C, Shelton WT, Sherman M, Thompson E, Yena P, Avedon MT, Bowen J, Gastier-Foster JM, Gerken M, Leraas KM, Lichtenberg TM, Ramirez NC, Santos T, Wise L, Zmuda E, Demchok JA, Felau I, Hutter CM, Sheth M, Sofia HJ, Tarnuzzer R, Wang Z, Yang L, Zenklusen JC, Zhang J, Ayala B, Baboud J, Chudamani S, Liu J, Lolla L, Naresh R, Pihl T, Sun Q, Wan Y, Wu Y, Ally A, Balasundaram M, Balu S, Beroukhim R, Bodenheimer T, Buhay C, Butterfield YS, Carlsen R, Carter SL, Chao H, Chuah E, Clarke A, Covington KR, Dahdouli M, Dewal N, Dhalla N, Doddapaneni HV, Drummond JA, Gabriel SB, Gibbs RA, Guin R, Hale W, Hawes A, Hayes DN, Holt RA, Hoyle AP, Jefferys SR, Jones SJ, Jones CD, Kalra D, Kovar C, Lewis L, Ma Y, Marra MA, Mayo M, Meng S, Meyerson M, Mieczkowski PA, Moore RA, Morton D, Mose LE, Mungall AJ, Muzny D, Parker JS, Perou CM, Roach J, Schein JE, Schumacher SE, Shi Y, Simons JV, Sipahimalani P, Skelly T, Soloway MG, Sougnez C, Tam A, Tan D, Thiessen N, Veluvolu U, Wang M, Wilkerson MD, Wong T, Wu J, Xi L, Zhou J, Bedford J, Chen F, Fu Y, Gerstein M, Haussler D, Kasaian K, Lai P, Ling S, Radenbaugh A, Van Den Berg D, Weinstein JN, Zhu J, Albert M, Alexopoulou I, Andersen JJ, Auman JT, Bartlett J, Bastacky S, Bergsten J, Blute ML, Boice L, Bollag RJ, Boyd J, Castle E, Chen YB, Cheville JC, Curley E, Davies B, DeVolk A, Dhir R, Dike L, Eckman J, Engel J, Harr J, Hrebinko R, Huang M, Huelsenbeck-Dill L, Iacocca M, Jacobs B, Lobis M, Maranchie JK, McMeekin S, Myers J, Nelson J, Parfitt J, Parwani A, Petrelli N, Rabeno B, Roy S, Salner AL, Slaton J, Stanton M, Thompson RH, Thorne L, Tucker K, Weinberger PM, Winemiller C, Zach LA, Zuna R; ''Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma.''; N Engl J Med, 2016 PubMed
  3. Fay AP, Signoretti S, Choueiri TK; ''MET as a target in papillary renal cell carcinoma.''; Clin Cancer Res, 2014 PubMed
  4. Appleman LJ; ''MET signaling pathway: a rational target for cancer therapy.''; J Clin Oncol, 2011 PubMed
  5. Giubellino A, Linehan WM, Bottaro DP; ''Targeting the Met signaling pathway in renal cancer.''; Expert Rev Anticancer Ther, 2009 PubMed
  6. Cecchi F, Rabe DC, Bottaro DP; ''Targeting the HGF/Met signalling pathway in cancer.''; Eur J Cancer, 2010 PubMed

History

View all...
CompareRevisionActionTimeUserComment
97130view19:00, 30 April 2018Khanspersupdated lit refs, updated connections
96851view19:39, 13 April 2018Khansperscorrected placement of states
96632view22:47, 23 March 2018Khanspersupdated Chebi ids
96629view19:28, 23 March 2018Khanspersupdating gene fusions
96628view18:11, 23 March 2018KhanspersModified description
96627view18:10, 23 March 2018Khanspersupdated phosphosites and mutations
96452view09:31, 15 March 2018EgonwReplaced secondary ChEBI identifiers with primary identifiers.
96109view00:16, 17 February 2018KhanspersModified title
96011view11:14, 15 February 2018DdiglesOntology Term : 'malignant cell' added !
95923view18:14, 5 February 2018Khanspersfixed unconnected
95850view22:02, 25 January 2018Khanspersadded Appleman ref
95849view22:00, 25 January 2018KhanspersModified title
95848view21:59, 25 January 2018KhanspersOntology Term : 'altered scatter factor/hepatocyte growth factor signaling pathway' added !
95847view21:58, 25 January 2018KhanspersOntology Term : 'papillary renal cell carcinoma' added !
95845view21:55, 25 January 2018Khanspersfixed unconnected
95824view21:51, 23 January 2018KhanspersModified description
95823view21:48, 23 January 2018KhanspersNew pathway

External references

DataNodes

View all...
NameTypeDatabase referenceComment
AKT1GeneProductENSG00000142208 (Ensembl)
AKT2GeneProductENSG00000105221 (Ensembl)
AKT3GeneProductENSG00000117020 (Ensembl)
ALKGeneProductENSG00000171094 (Ensembl)
ARAFGeneProductENSG00000078061 (Ensembl)
BADGeneProductENSG00000002330 (Ensembl)
BRAFGeneProductENSG00000157764 (Ensembl)
BUB1B-PAK6GeneProductENSG00000259288 (Ensembl)
C8orf34GeneProductENSG00000165084 (Ensembl)
CBLGeneProductENSG00000110395 (Ensembl)
CDC42GeneProductENSG00000070831 (Ensembl)
CRKGeneProductENSG00000167193 (Ensembl)
CRKLGeneProductENSG00000099942 (Ensembl)
Ca2+MetaboliteCHEBI:29108 (ChEBI)
DAGMetaboliteCHEBI:18035 (ChEBI)
ETS1GeneProductENSG00000134954 (Ensembl)
GAB1GeneProductENSG00000109458 (Ensembl)
GRB2GeneProductENSG00000177885 (Ensembl)
HGFGeneProductENSG00000019991 (Ensembl)
HRASGeneProductENSG00000174775 (Ensembl)
INSL3GeneProductENSG00000248099 (Ensembl)
IP3MetaboliteCHEBI:84244 (ChEBI)
JAK3GeneProductENSG00000105639 (Ensembl)
JUNGeneProductENSG00000177606 (Ensembl)
KRASGeneProductENSG00000133703 (Ensembl)
MAP2K1GeneProductENSG00000169032 (Ensembl)
MAP2K2GeneProductENSG00000126934 (Ensembl)
MAPK1GeneProductENSG00000100030 (Ensembl)
MAPK3GeneProductENSG00000102882 (Ensembl)
MAPK8GeneProductENSG00000107643 (Ensembl)
METGeneProduct4233 (Entrez Gene)
NRASGeneProductENSG00000213281 (Ensembl)
PAK1GeneProductENSG00000149269 (Ensembl)
PAK2GeneProductENSG00000180370 (Ensembl)
PAK3GeneProductENSG00000077264 (Ensembl)
PAK4GeneProductENSG00000130669 (Ensembl)
PAK5GeneProductENSG00000101349 (Ensembl)
PAK6GeneProductENSG00000137843 (Ensembl)
PIK3CAGeneProductENSG00000121879 (Ensembl)
PIK3CBGeneProductENSG00000051382 (Ensembl)
PIK3CDGeneProductENSG00000171608 (Ensembl)
PIK3R1GeneProductENSG00000145675 (Ensembl)
PIK3R2GeneProductENSG00000105647 (Ensembl)
PIK3R3GeneProductENSG00000117461 (Ensembl)
PIP3MetaboliteCHEBI:16618 (ChEBI)
PKCGeneProduct
PLCG1GeneProductENSG00000124181 (Ensembl)
PTK2GeneProductENSG00000169398 (Ensembl)
PTPN11GeneProductENSG00000179295 (Ensembl)
PTPsGeneProduct
RAC1GeneProductENSG00000136238 (Ensembl)
RAF1GeneProductENSG00000132155 (Ensembl)
RAP1AGeneProductENSG00000116473 (Ensembl)
RAP1BGeneProductENSG00000127314 (Ensembl)
RAPGEF1GeneProductENSG00000107263 (Ensembl)
RPL11GeneProductENSG00000142676 (Ensembl)
SOS1GeneProductENSG00000115904 (Ensembl)
SOS2GeneProductENSG00000100485 (Ensembl)
SRCGeneProductENSG00000197122 (Ensembl)
STAT3GeneProductENSG00000168610 (Ensembl)
STRNGeneProductENSG00000115808 (Ensembl)
TCEB3GeneProductENSG00000011007 (Ensembl)
VEGFGeneProduct
VEGFRGeneProduct
foretinibMetaboliteQ5469311 (Wikidata)
tivantinibMetaboliteQ17123902 (Wikidata)

Annotated Interactions

No annotated interactions

Personal tools